Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) announced a study published in the journal Lung Cancer, highlighting the effectiveness of next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) for detecting ALK fusions in lung cancer patients. Conducted in collaboration with Resolution Bioscience and Memorial Sloan Kettering Cancer Center, the study emphasizes the non-invasive nature and clinical utility of this method. Findings suggest that ctDNA testing can monitor resistance mechanisms in patients undergoing targeted therapy, supporting precision oncology.
Summary not available.
Agilent Technologies Inc. (NYSE: A) will announce its third-quarter fiscal year 2021 financial results on Tuesday, August 17, after market close. A live webcast for the investor conference call will occur the same day at 1:30 p.m. Pacific time, accessible via the Investor Relations section of Agilent's website. The company reported revenues of $5.34 billion in fiscal year 2020 and employs 16,400 individuals globally. The webcast will be available for 90 days following the event.
Agilent Technologies (NYSE: A) has expanded the labeling of its PD-L1 IHC 22C3 pharmDx assay for use in patients with non-small cell lung cancer (NSCLC) in the European Union. The assay helps identify NSCLC patients with Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab). Lung cancer is the leading cause of cancer death, with NSCLC accounting for about 85% of cases. This initiative underscores Agilent's commitment to developing diagnostics for targeted cancer therapy.
Agilent Technologies Inc. (NYSE: A) has launched a new eMethod for PFAS Analysis in Water using liquid chromatography and mass spectrometry. This solution enables rapid testing for over 100 PFAS compounds in drinking and surface water, significantly reducing analysis time from weeks to hours. The method aligns with evolving global regulations, helping environmental customers update their testing protocols. The comprehensive analytical workflow includes sample preparation, acquisition, and quantitation methods, ensuring compliance with current and future regulations.
MOBILion Systems Inc. has successfully completed a $60 million Series C financing round, led by D1 Capital Partners. This funding will support the commercialization of its first product, MOBIE®, a High-Resolution Ion Mobility tool designed for biopharmaceutical drug development. The technology aims to enhance the speed and accuracy of protein characterization, vital for quality monitoring in drug development. The company plans to expand its market presence, particularly in emerging fields like cell and gene therapy.
Agilent Technologies Inc. (NYSE: A) announced a significant study in partnership with Resolution Bioscience and Dana-Farber Cancer Institute, published in the New England Journal of Medicine. The study explores the clinical utility of liquid biopsy techniques for detecting resistance to KRAS G12C inhibitors like adagrasib in cancer treatment. It reveals diverse mutations leading to resistance, emphasizing the need for new therapeutic strategies. Notably, cfDNA analysis enabled more effective genotyping, improving patient outcomes in targeted therapies.
Agilent Technologies Inc. (NYSE: A) has launched three new InfinityLab Bio LC systems tailored for the biopharma industry. This portfolio includes the 1290 Infinity II Bio LC System with High-Speed Pump, 1290 Infinity II Bio LC System with Flexible Pump, and 1260 Infinity II Prime Bio LC System. These systems integrate with Agilent OpenLab and MassHunter software, enhancing efficiency in biopharma laboratories. The launch highlights Agilent's commitment to the growing biopharma LC market and introduces new workflow solutions to support bio-analytical requirements.
Summary not available.
Agilent Technologies (NYSE: A) announced a presentation at the American Society of Clinical Oncology (ASCO) featuring the Resolution ctDx Lung test from Resolution Bioscience. The study, with over 1,000 patients, provides evidence for the clinical utility of this liquid biopsy in guiding targeted therapies for non-small cell lung cancer (NSCLC), showing a significant overall survival benefit. The findings highlight the advantages of liquid biopsies over traditional tissue tests, asserting Agilent's commitment to enhancing cancer diagnostics and precision oncology solutions.